Express News | Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for Rsv and Malaria Using C1 Platform Technology
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript Summary
HC Wainwright & Co. Reiterates Buy on Dyadic International, Maintains $6 Price Target
Dyadic International Reports Q3 2024 Growth and Strategic Advances
Dyadic Intl 3Q Rev $1.9M >DYAI